A clinical trial testing the effectiveness of the weekly combination of paclitaxel, doxorubicin and cyclophosphamide with the AKT inhibitor MK-2206 as a preoperative treatment for breast cancer revealed a significantly improved rate of complete tumor disappearance (40%) when compared with chemotherapy alone (22%) (175). The gene discussed is AKT1; the disease is neoplasm.